1. Home
  2. LOCO vs TRDA Comparison

LOCO vs TRDA Comparison

Compare LOCO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$10.67

Market Cap

325.6M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.54

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCO
TRDA
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.6M
404.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
LOCO
TRDA
Price
$10.67
$11.54
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$14.50
$20.00
AVG Volume (30 Days)
181.1K
200.0K
Earning Date
03-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
13.62
N/A
EPS
0.89
N/A
Revenue
$480,815,000.00
$61,520,000.00
Revenue This Year
$5.44
N/A
Revenue Next Year
$1.64
$3.14
P/E Ratio
$12.30
N/A
Revenue Growth
2.09
N/A
52 Week Low
$8.29
$4.93
52 Week High
$12.65
$14.27

Technical Indicators

Market Signals
Indicator
LOCO
TRDA
Relative Strength Index (RSI) 44.11 60.33
Support Level $10.83 $10.34
Resistance Level $11.24 $12.18
Average True Range (ATR) 0.32 0.75
MACD -0.02 0.08
Stochastic Oscillator 29.02 72.98

Price Performance

Historical Comparison
LOCO
TRDA

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: